GGrantIndex
Sort

39,280 grants matching leukemia

RepServer: Antigen Receptor Repertoire Analysis Pipelines via the WWW

$641,471
Lindsay G. Cowell · Ut Southwestern Medical Center · R01 · FY2014 · AI

Teens at Risk: Prenatal Cocaine and Postnatal Challenges

$641,387
Virginia Delaney-Black · Wayne State University · R01 · FY2012 · DA

Studies of Host Cellular Proteins Required for viral Budding and release

$641,279
Fadila Bouamr · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias

$641,266
Jian Jin · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia

$641,161
Daniel Bachovchin · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA

Functional and translational studies of RUNX1 and CBFB in hematopoiesis

$641,111
Paul Liu · National Human Genome Research Institute · ZIA · FY2015 · HG

Molecular mechanisms of allele-specific NRAS signaling and tumorigenesis

$640,969
Christin E Burd · Ohio State University · R01 · FY2024 · CA

Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner

$640,960
G Greg Wang · Duke University · R01 · FY2025 · CA

Towards rational design of combination therapeutic targets

$640,892
Kai Tan · Children'S Hosp Of Philadelphia · U01 · FY2021 · CA

Preclinical Testing of PI3K Inhibitors for Vestibular Schwannomas

$640,803
Cristina Maria Fernandez-Valle · University Of Central Florida · R01 · FY2020 · DC

Understanding the Increased Risk of Childhood Acute Lymphoblastic Leukemia in Latinos

$640,629
Adam De Smith · University Of Southern California · R01 · FY2023 · CA

Genetic Epidemiology of Chronic Lymphocytic Leukemia

$640,314
Susan L Slager · Mayo Clinic Rochester · U01 · FY2010 · CA

Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical Insights

$640,150
Bing Zhang · Baylor College Of Medicine · U24 · FY2025 · CA

Overcoming resistance to menin patient mutations in leukemia

$640,135
Jolanta Grembecka · University Of Michigan At Ann Arbor · R01 · FY2025 · CA

Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia

$640,103
Peter Kurre · Children'S Hosp Of Philadelphia · R01 · FY2023 · HL

Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy

$639,740
A Thomas Look · Dana-Farber Cancer Inst · P01 · FY2013 · CA

Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance

$639,689
Neil P Shah · University Of California, San Francisco · R01 · FY2023 · CA

Role of TET2 mutations in malignant transformation and acute myeloid leukemia

$639,626
Ross L Levine · Sloan-Kettering Inst Can Research · R01 · FY2015 · CA

Role of TET2 mutations in malignant transformation and acute myeloid leukemia

$639,626
Ross L Levine · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA

Role of TET2 mutations in malignant transformation and acute myeloid leukemia

$639,626
Ross L Levine · Sloan-Kettering Inst Can Research · R01 · FY2016 · CA

Impact of low IL-10 levels at birth and leukemia risk

$639,604
Joseph Leo Wiemels · University Of California, San Francisco · R01 · FY2015 · CA

Developmental Funds

$639,485
Raphael E. Pollock · Ohio State University · P30 · FY2024 · CA

Developmental Funds

$639,483
Raphael E. Pollock · Ohio State University · P30 · FY2023 · CA

Developmental Funds

$639,483
Raphael E. Pollock · Ohio State University · P30 · FY2022 · CA

Developmental Funds

$639,483
Raphael E. Pollock · Ohio State University · P30 · FY2021 · CA